ABSTRACT
Abstract The aim of the present study was to investigate the usefulness of multidrug resistance protein 1 (MDR1) and neuropeptide Y (NPY) levels in predicting the efficacy of levetiracetam (LEV) plus oxcarbazepine (OXC) treatment administered to children with epilepsy and to determine their prognosis. Overall, 193 children with epilepsy admitted to the hospital were enrolled and randomly divided into two groups according to different treatment methods: group A (n = 106, treated with LEV plus OXC combination) and group B (n = 87, treated with OXC only). After treatment, compared with group B, group A exhibited a remarkably higher total effective rate and a significantly lower total adverse reaction rate. Areas under the curve for MDR1 and NPY for predicting ineffective treatment were 0.867 and 0.834, whereas those for predicting epilepsy recurrence were 0.916 and 0.829, respectively. Electroencephalography abnormalities, intracranial hemorrhage, neonatal convulsion, premature delivery, and MDR1 and NPY levels were independent risk factors for poor prognosis in children with epilepsy. Serum MDR1 and NPY levels exhibited a high predictive value for early epilepsy diagnosis, treatment efficacy assessment, and prognostication in children with epilepsy treated with LEV plus OXC combination.
Subject(s)
Humans , Male , Female , Neuropeptide Y/analysis , Child , ATP Binding Cassette Transporter, Subfamily B, Member 1/analysis , Epilepsy/pathology , Levetiracetam/antagonists & inhibitors , Oxcarbazepine/antagonists & inhibitors , Efficacy , Electroencephalography/methodsABSTRACT
Abstract Paclitaxel (PTX) is one of the most effective drugs used in the treatment of breast cancer. Nonetheless, the appearance of MDR1 (multidrug resistance 1) in tumor cells has become a significant hindrance for efficacious chemotherapy. In this study, we show that the expression level of Egr-1 (early growth response gene-1) in cancer tissues (from paclitaxel chemotherapy failure patients) and MCF-7/PTX cells (the breast cancer cell line that was resistant to paclitaxel) was increased. Cell proliferation assay and apoptosis assay revealed that Egr-1 could promote cell growth and inhibit apoptosis in MCF-7/PTX. Mechanistic studies indicated that Egr-1 could bind to the proximal MDR1 promoter and enhance MDR1 transcription. These findings indicate that paclitaxel induced Egr-1 accumulation and upregulated the expression of MDR1, thereby inducing the drug resistance in MCF-7/PTX. Our results suggest a novel pathway by which paclitaxel induces MDR1 expression, possibly illuminating a potential target pathway for the prevention of MDR1-mediated drug resistance.
Subject(s)
Breast Neoplasms/pathology , Drug Resistance , ATP Binding Cassette Transporter, Subfamily B, Member 1/analysis , Pharmaceutical Preparations/analysisABSTRACT
Clitoria ternateaL. is a vital ayurvedic herbfeatured with a wide spectrum of mental health benefits. The present study investigates the competence of the plant against depression and to inhibit the membrane efflux protein P-glycoprotein (P-gp) that can regulate and restrict drug permeation into the brain. Antidepressant competence of the aqueous plant extract was assessed by animal despair studies on depression induced female mice models. The P-glycoprotein inhibitory potential of active phytocompounds was evaluated by molecular docking assay and substantiated by a cell line study. The in vivostudies exhibited a significant difference in the immobility time thereby establishing antidepressant activity. The histopathological sections from cortex region of treated brain showed decreased degenerative changes. Ten imperative phytocompounds facilitated docking complexes against P-glycoprotein among which Kaempferol 3-O-(2״,6״-di-O-rhamnopyranosyl) glucopyranoside exhibited a finest docking score of -12.569 kcal mol-1. Conversely it was attested by the rhodamine transport assay that demonstrated the inhibitory potential to surpass blood brain barrier. The outcome of the study endorses the efficacy of Clitoria ternateaL. as an idyllic brain drug and facilitates brain permeability.
Subject(s)
Antidepressive Agents , Medicine, Ayurvedic , Blood-Brain Barrier , Biotechnology , ATP Binding Cassette Transporter, Subfamily B, Member 1/analysisABSTRACT
Para fármacos administrados por via oral, o controle da extensão e da velocidade de absorção depende basicamente de duas importantes etapas: solubilidade do fármaco nos líquidos fisiológicos e sua permeabilidade através das membranas biológicas. Assim, o Sistema de Classificação Biofarmacêutica (SCB) foi proposto como uma ferramenta para o desenvolvimento de novos fármacos, de novas formulações e para auxiliar nos processos de bioisenção. No entanto, outro fator relacionado à biodisponibilidade e que deve ser considerado nos estudos biofarmacêuticos é o metabolismo. Desta forma, o Sistema de Classificação Biofarmacêutica de Distribuição de Fármacos (SCBDF) foi proposto com a finalidade de classificar os fármacos de acordo com suas características de solubilidade e de metabolismo de modo que seja possível avaliar e predizer o comportamento do fármaco in vivo. O metabolismo tem sido amplamente investigado, sobretudo as enzimas do citocromo P450, as quais estão presentes também nos enterócitos. Além disso, o SCBDF oferece um suporte quanto à avaliação dos mecanismos de permeabilidade envolvidos nos processos de absorção, interações fármaco-fármaco e interações fármaco-alimento. Assim, o presente trabalho teve como objetivo elucidar os mecanismos envolvidos na permeabilidade de fármacos antirretrovirais por meio dos modelos ex vivo (câmaras de difusão vertical tipo Franz) e in vitro (PAMPA, MDCK-MDR1 e microssomas) considerando os aspectos relacionados ao metabolismo intestinal e ao efluxo destes fármacos. Dada a importância da utilização de fármacos antirretrovirais na terapia medicamentosa contra a Síndrome da Imunodeficiência Adquirida (SIDA) e que estes medicamentos são normalmente administrados cronicamente, a compreensão dos mecanismos envolvidos na permeabilidade é de suma importância, uma vez que estes não estão totalmente esclarecidos e poucas informações são encontradas na literatura. Além disso, a biodisponibilidade de fármacos como estavudina, lamivudina e zidovudina indica variação na permeabilidade, necessitando de uma investigação científica mais aprofundada dos processos absortivos. Assim, segmentos de jejuno provenientes de ratos machos Wistar foram utilizados para a avaliação da permeabilidade intestinal dos referidos antirretrovirais considerando a avaliação de efluxo pela glicoproteína-P e o metabolismo intestinal pela CYP3A. De maneira complementar, estudos in vitro com o emprego de membranas artificiais paralelas (PAMPA) e culturas celulares de MDCK-MDR1 foram realizados com a finalidade de auxiliar na elucidação dos mecanismos de permeabilidade dos fármacos antirretrovirais. Além disso, a avaliação do metabolismo dos referidos fármacos foi realizada com o emprego de microssomas a fim de verificar se tais substâncias são substratos de enzimas da família CYP3A e, assim, verificar o impacto do metabolismo intestinal na absorção. Os resultados de permeabilidade obtidos em PAMPA foram: 0,74±0,11 x 10-6 cm/s para a estavudina, 0,25±0,12 x 10-6 cm/s para a lamivudina e 1,14±0,25 x 10-6 cm/s para a zidovudina. Já no modelo ex vivo com o emprego de câmaras de difusão vertical tipo Franz, os resultados foram: 1,56±0,32 x 10-5 cm/s para a estavudina, 1,26±0,27 x 10-5 cm/s para a lamivudina e 2,54±0,49 x 10-5 cm/s para a zidovudina. Portanto, com base nos resultados obtidos a partir dos dois métodos empregados, sugere-se que 30 outro mecanismo de transporte que não envolva a permeabilidade por difusão transcelular passiva possa estar relacionado à permeabilidade dos fármacos antirretrovirais. Com relação aos estudos de efluxo, os resultados obtidos a partir dos experimentos realizados em câmaras de difusão vertical tipo Franz demonstraram o aumento significativo da permeabilidade dos três antirretrovirais quando o inibidor de P-gp foi empregado, sendo: de 15,6 x 10-6 para 42,5 x 10-6 cm/s para a estavudina, de 12,6 x 10-6 para 37,5 x 10-6 cm/s para a lamivudina e de 25,4 x 10-6 para 56,6 x 10-6 cm/s para a zidovudina. Em culturas celulares MDCK-MDR1, os resultados de permeabilidade foram utilizados para a obtenção das razões entre as direções BâA e AâB. Os valores de Papp na condição inibida para os fármacos estudados apresentaram razão menor do que 1. Já a razão BâA/AâB para cada fármaco nos ensaios sem inibidor apresentou-se igual ou maior que 2, evidenciando a interação fármaco-transportador. Com base nisso, o modelo ex vivo com o emprego de segmentos intestinais em câmaras de difusão vertical tipo Franz apresentou-se adequado na avaliação do mecanismo de efluxo dos fármacos antirretrovirais, o que foi confirmado com os estudos realizados em MDCK-MDR1. Assim, os fármacos antirretrovirais estudados apresentaram interação significativa com a P-gp. Em relação aos estudos de metabolismo realizados em câmaras de difusão vertical tipo Franz, os resultados demonstraram grande variação na permeabilidade dos três antirretrovirais quando o inibidor de CYP3A foi empregado, sendo: de 15,6 x 10-6 para 23,5 x 10-6 cm/s para a estavudina, de 12,6 x 10-6 para 27,3 x 10-6 cm/s para a lamivudina e de 25,4 x 10-6 para 40,5 x 10-6 cm/s para a zidovudina. Já no modelo que emprega microssomas, os resultados de metabolização na ausência e na presença de inibidor de CYP3A foram: de 16,56% para 19,79% para a estavudina, de 14,56% para 15,55% para a lamivudina e de 17,85% para 16,48% para a zidovudina. Com base nisso, sugerese o emprego de microssomas para a determinação de metabolismo, uma vez que o método ex vivo empregado demonstrou grande variação entre os valores obtidos. Desta forma, observou-se que, para cada fármaco, não houve influência significativa no metabolismo pré-sistêmico relacionado às enzimas do complexo CYP3A, o que indica que a absorção oral das referidas substâncias não é limitada por tais enzimas. Portanto, a utilização dos diferentes métodos empregados no desenvolvimento do presente trabalho permitiu compreender os mecanismos envolvidos no transporte dos fármacos antirretrovirais, o que se torna de grande relevância nas etapas de desenvolvimento farmacêutico de novas moléculas e na compreensão de eventos clínicos ainda não esclarecidos atualmente
For orally administered drugs, control of the extent and rate of absorption depends on two important steps: solubility of the drug in physiological liquids and their permeability across biological membranes. Thus, the Biopharmaceutics Classification System (BCS) has been proposed as a tool for the development of new drugs, new formulations and aid in the biowaiver processes. However, another factor related to bioavailability that should be considered in biopharmaceutic studies is the metabolism. Thus, the Biopharmaceutics Drug Disposition Classification System (BDDCS) has been proposed for drug classification according to their solubility and metabolism characteristics, so it is possible to evaluate and predict the in vivo behavior of a compound. Metabolism has been extensively investigated, especially cytochrome P450 enzymes, which are also expressed in enterocytes. Besides, BDDCS provides support in evaluating the permeability mechanisms involved in the absorption processes, drug-drug interactions and drug-food interactions. Thus, the present study aimed to evaluate the mechanisms of permeability of antiretroviral drugs through the ex vivo (Franz cells) and in vitro (PAMPA, MDCK-MDR1 and microsomes) models considering aspects related to the intestinal metabolism and efflux of these drugs. Given the importance of the use of antiretroviral drugs in drug therapy against Acquired Immune Deficiency Syndrome (AIDS) and that these drugs are usually administered in a long-term way, understanding the mechanisms involved in the permeability is of a great importance, since they are not totally elucidated and no information is found in the literature. In addition, drugs as stavudine, lamivudine and zidovudine indicate variation in the permeability, which require further scientific investigation of absorptive processes. Thus, jejunum segments from rats were used to evaluate the intestinal permeability of these antiretroviral drugs, considering the evaluation of efflux by P-glycoprotein and intestinal metabolism by CYP3A. In a complementary manner, in vitro studies using parallel artificial membranes (PAMPA) and cell cultures MDCK-MDR1 were performed to aid in the elucidation of the permeability mechanisms of antiretroviral drugs. Also, the evaluation of the metabolism was carried out using microsomes to verify if such substances are substrates of CYP3A, and verify the impact of the intestinal metabolism in the absorption. The permeability results obtained in PAMPA were: 0.74±0.11x10-6 cm/s for stavudine, 0.25±0.12x10-6 cm/s for lamivudine and 1.14±0.25x10-6 cm/s for zidovudine. In ex vivo method using the intestinal segments in Franz cells, the results were: 1.56±0.32x10-5 cm/s for stavudine, 1.26±0.27x10-5 cm/s for lamivudine and 2.54±0.49x10-5 cm/s for zidovudine. Thus, based on the results obtained from these two methods, it is suggested that the antiretroviral drugs present other transport mechanism that is different from transcellular passive diffusion. For efflux studies, results obtained from experiments performed in Franz cells shown the increase of the permeability of the three antiretroviral drugs when the P-gp inhibitor was used: from 15.6x10-6 to 42,5x10-6 cm/s for stavudine, from 12.6x10-6 cm/s to 37.5x10-6 cm/s for lamivudine, and 25.4x10-6 to 56.6x10-6 cm/s for zidovudine. In MDCK-MDR1, the permeability results were used for obtaining ratio values between the directions BâA and AâB. The Papp values obtained with 33 inhibitor shown a ratio less than 1. For ratio BâA/AâB for each drug in experiments without inhibitor, the values obtained was equal or greater than 2, which shows the interaction between drug and transporter. Based on that, the ex vivo model using intestinal segments in Franz cells seems to be adequate for evaluation of efflux mechanism of antiretroviral drugs, which was confirmed by MDCK-MDR1 studies. Thus, the antiretroviral drugs presented interaction with P-gp. For metabolism studies in intestinal segments in Franz cells, a wide range of standard deviation was observed for the three antiretroviral drugs when the CYP3A inhibitor was used: from 15.6x10-6 cm/s to 23.5x10-6 cm/s for stavudine, from 12.6x10-6 cm/s to 27.3x10-6 cm/s for lamivudine, and from 25.4x10-6 cm/s to 40.5x10-6 cm/s for zidovudine. In experiments in microsomes, the results of metabolization in the absence and presence of CYP3A inhibitor were: from 16.56 to 19.79% for stavudine, from 14.56 to 15.55% for lamivudine and from 17.85 to 16.48% for zidovudine. Based on that, it is suggested the use of microsomes for metabolism evaluation, since the ex vivo method presented high variability between the results obtained. For each drug, no significative influence in pre-systemic metabolism related to CYP3A enzymes was observed, which indicates that the oral absorption of the drugs is not limited by these enzymes. The use of different methods in this work allowed to understand the mechanisms involved in the transport of antiretroviral drugs, which is of a great relevance in drug development and in the understanding of clinical events currently not clarified
Subject(s)
Anti-Retroviral Agents/supply & distribution , Evaluation Studies as Topic/classification , Permeability , Pharmaceutical Preparations/administration & dosage , Laboratory and Fieldwork Analytical Methods/methods , Biopharmaceutics/classification , Cytochrome P-450 CYP3A/pharmacology , ATP Binding Cassette Transporter, Subfamily B, Member 1/analysis , Spectrophotometry/methods , Validation StudyABSTRACT
The present study was planned to investigate the influence of polyethylene glycols (PEGs) on the activity and expression of P-glycoprotein (P-gp). Sub-toxic concentrations of PEGs in Caco-2 cells were determined using the MTT test assay. Then the measurement of Rhodamine-123 (Rho-123) uptake, a P-gp fluorescence substrate, in Caco-2 cells confronting PEG 400 (1% and 2% w/v), PEG 4000 (2% and 4% w/v), PEG 6000 (2% and 4% w/v), PEG 10000 (2% and 4% w/v), PEG 15000 (1% and 2% w/v), and PEG 35000 (2% and 4% w/v) overnight was taken to elucidate whether non-toxic concentrations of PEGs are able to impact P-gp activity. Furthermore, western blotting was carried out to investigate P-gp protein expression. The results showed that PEG 400 at concentrations of 1% (w/v) and 2% (w/v) and PEG 6000 at the concentration of 4% (w/v) are notably capable of blocking P-gp. Based on the obtained results it is concluded that the mentioned excipients could be used to obstruct P-gp efflux transporter in order to increase the bioavailability of co-administered substrate drug.
O presente estudo foi planejado para investigar a influência de polietileno glicóis sobre a atividade e expressão da P- glicoproteína (P-gp) . Concentrações sub-tóxicas de PGPs e em células Caco-2 foram determinadas por meio do ensaio de MTT. Em seguida, efetuou-se a a medida de captura de Rodamina-123 (Rho-123), um substrato fluorescente de P-gp, em células Caco-2, confrontando com PEG 400 (1% e 2% m/v), PEG 4000 (2% e 4% m/v) e PEG 6000 (2% e 4% m /v), PEG 10000 (2% e 4% w/v), PEG 15000 (1% e 2% m/v), e PEG 35000 (2% e 4% m/v). Essa medida foi efetuada durante a noite, para saber se as concentrações não tóxicas de excipientes são capazes de influenciar a actividade da P-gp. Além disso, realizou-se o western blotting para investigar a expressão da proteína P-gp. Os resultados mostraram que o PEG 400, nas concentrações de 1% (m/v) e 2% (m/v), e PEG 6000, na concentração de 4% (m/v) são capazes de bloquear P-gp. Com base nos resultados conclui-se que os excipientes mencionados poderiam ser utilizados para obstruir o efluxo por P-gp, a fim de aumentar a biodisponibilidade de do fármaco co-administrado.
Subject(s)
Polyethylene Glycols/analysis , ATP Binding Cassette Transporter, Subfamily B, Member 1/analysis , Caco-2 Cells , Biological Availability , Rhodamine 123 , Excipients/classificationABSTRACT
P-glycoprotein (P-gp), a transmembrane permeability glycoprotein, is a member of ATP binding cassette (ABC) super family that functions specifically as a carrier mediated primary active efflux transporter. It is widely distributed throughout the body and has a diverse range of substrates. Several vital therapeutic agents are substrates to P-gp and their bioavailability is lowered or a resistance is induced because of the protein efflux. Hence P-gp inhibitors were explored for overcoming multidrug resistance and poor bioavailability problems of the therapeutic P-gp substrates. The sensitivity of drug moieties to P-gp and vice versa can be established by various experimental models in silico, in vitro and in vivo. Ever since the discovery of P-gp, the research plethora identified several chemical structures as P-gp inhibitors. The aim of this review was to emphasize on the discovery and development of newer, inert, non-toxic, and more efficient, specifically targeting P-gp inhibitors, like those among the natural herb extracts, pharmaceutical excipients and formulations, and other rational drug moieties. The applications of cellular and molecular biology knowledge, in silico designed structural databases, molecular modeling studies and quantitative structure-activity relationship (QSAR) analyses in the development of novel rational P-gp inhibitors have also been mentioned.
Glicoproteína-p (P-gp), uma glicoproteína de transmembrana permeável, é um membro da superfamília (ABC) de cassete de gene de ligação de ATP que funciona especificamente como um carreador mediado pelo transportador de efluxo ativo primário. É amplamente distribuído por todo o corpo e apresenta uma gama diversificada de substratos. Diversos agentes terapêuticos vitais são substratos para P-gp e sua biodisponibilidade é reduzida ou a resistência é induzida devido ao efluxo de proteínas. Portanto, os inibidores da P-gp foram explorados para a superação da resistência a múltiplas drogas e problemas de biodisponibilidade deficiente dos substratos terapêuticos da P-gp. A sensibilidade das moléculas da droga à P-gp e vice-versa, pode ser estabelecida por vários modelos experimentais in silico, in vitro e in vivo. Desde a descoberta da P-gp, diversas pesquisas identificaram várias estruturas químicas como inibidores da P-gp. O objetivo deste presente estudo foi o de enfatizar a descoberta e desenvolvimento de inibidores mais novos, inertes, atóxicos e mais eficazes, visando especificamente os da P-gp, como aqueles entre os extratos vegetais, excipientes e formulações farmacêuticas, e outras moléculas racionais de droga. As aplicações do conhecimento de biologia celular e molecular, bancos de dados estruturais in silico, estudos de modelagem molecular e análises da relação quantitativa estrutura-atividade (QSAR) no desenvolvimento de novos inibidores racionais da P-gp também foram mencionados.
Subject(s)
ATP Binding Cassette Transporter, Subfamily B, Member 1/analysis , ATP Binding Cassette Transporter, Subfamily B, Member 1/adverse effects , Sphingolipids/analysis , Drug Resistance, MultipleABSTRACT
INTRODUÇÃO: Osteossarcoma (OS), o mais freqüente tumor primário maligno do osso, tem comportamento local agressivo e alto índice de disseminação sistêmica. Os eventos que permitem o crescimento e a disseminação tumoral ainda permanecem controversos. Os estudos sobre a carcinogênese e a progressão dessa neoplasia, com base na imunoexpressão de c-erb-B2, P-glicoproteína (P-gp) e p53, apresentam resultados conflitantes acerca do real valor prognóstico e suas correlações com parâmetros histológicos. A anaplasia, em neoplasias na infância, constitui parâmetro histológico de agressividade tumoral e quimiorresistência. Nos OS primários ou metastáticos, seu significado permanece controverso. Por outro lado, em outras neoplasias humanas, a expressão do c-erb-B2 relaciona-se com p53, grau nuclear e outros parâmetros de agressividade. OBJETIVO: Avaliar a imunoexpressão de p53, c-erb-B2 e P-gp em OS, correlacionando os parâmetros entre si e com a presença de anaplasia. MÉTODO: O estudo incluiu 96 biópsias pré-quimioterapia de pacientes com OS de alto grau, diagnosticados entre 1991 e 2000. A pesquisa imuno-histoquímica de p53, P-gp e c-erb-B2 foi feita pela técnica da estreptoavidina-biotina-peroxidase. Foram considerados positivos os casos onde havia imunoexpressão em 10 por cento ou mais das células neoplásicas. Somente colorações membranosa (para cerb-B2 e P-gp) e nuclear (para p53) foram consideradas positivas. Anaplasia foi definida como no tumor de Wilms, sendo considerada presente ou ausente. RESULTADOS: Anaplasia pôde ser avaliada em 82/96 casos, estando presente em 29 (35,36 por cento). Imunoexpressão de p53 foi detectada em 25 dos 60 casos (36,23 por cento); de P-gp, em 30 dos 73 casos (41,1 por cento); e de c-erb-B2, em 22 dos 55 casos (40 por cento). Os resultados demonstraram associação entre as imunoexpressões de c-erb-B2 e p53 (p = 0,042), p53 e o parâmetro anaplasia (p = 0,015), anaplasia e Pg (p = 0.034) CONCLUSÕES: A imunoexpressão...
BACKGROUND: Osteosarcomas (OS), the most frequent primary malignant bone tumors, have aggressive local behavior and high rate of metastatization. The events that allow tumor growth and dissemination are still controversial. The studies about carcinogenesis and tumor progression in this neoplasia, which are based on c-erb-B2, P-glycoprotein (P-gp) and p53 immunoexpression, show conflicting results as to the real prognostic value and its correlations with histological parameters. Anaplasia in childhood neoplasias is a histological parameter of tumor aggressiveness and chemoresistance. In primary or metastatic OS, its meaning remains controversial. On the other hand, in other human neoplasias, c-erb-B2 expression is associated with p53, nuclear grade and other aggressiveness parameters. OBJECTIVE: The aim of the present study was to evaluate p53, c-erb-B2 and P-gp immunoexpression in OS, correlating the parameters with the presence of anaplasia. METHODS: This study included 96 pre-chemotherapy biopsies in patients with high-grade OS diagnosed between 1991 and 2000. The immunohistochemical evaluation of p53 and c-erb-B2 was carried out with the streptavidin-biotin-peroxidase technique. Cases were considered positive when there was immunoexpression in 10 percent or more neoplastic cells. Only membrane staining (for c-erb-B2 and P-gp), and nuclear staining (for p53) were considered positive. Anaplasia was defined as Wilms' tumor, and considered present or absent. RESULTS: Anaplasia was present in 29 out of 82 cases (35.36 percent); p53 immunoexpression was detected in 25 out of 60 cases (36.23 percent); P-gp, in 30 out of 73 cases (41.1 percent); and c-erb-B2, in 22 out of 55 cases (40 percent). The results demonstrated an association between c-erb-B2 and p53 immunoexpression (p = 0.042), p53 and parameter of anaplasia (p = 0.015), anaplasia and P-gp (p = 0.034). CONCLUSIONS: The p53, c-erb-B2 and P-gp immunoexpression is relatively frequent in high-grade, metastic...
Subject(s)
Humans , Male , Female , Child, Preschool , Child , Adolescent , Adult , Middle Aged , Anaplasia/diagnosis , ATP Binding Cassette Transporter, Subfamily B, Member 1/analysis , Immunohistochemistry , Osteosarcoma , /analysis , /analysis , Biomarkers, Tumor/analysis , OsteosarcomaABSTRACT
BACKGROUND: P-Glycoprotein (P-gp), a product of the MDR-1 gene, is a transmembrane efflux pump involved in drug transport, first described in cancer refractoriness. In the normal bowel P-gp is detectable on superficial epithelial cells, but has not been described in crypt epithelium. The role of P-gp and its intestinal expression in steroid-refractory ulcerative colitis (UC) are controversial. AIM: to compare P-gp immunostaining pattern in colonic epithelial cells of steroid-refractory versus steroid-responder UC patients. METHODS: P-gp was assessed by immunohistochemistry in rectal biopsies obtained from 19 patients with active UC, including pre-surgical samples from 11 refractory patients who underwent colectomy, and 8 responders. We devised a 5-point (0-4) score, according to the percentage of epithelial surface with positive immunostaining in the superficial and crypt epithelium (apical, lateral and cytoplasmic areas). RESULTS: Compared with responders, steroid-refractory patients had significantly higher immunostaining scores in the superficial epithelium, both in apical (2.8+/-0.5 versus 1.1+/-0.5, p=0.023) and cytoplasmic cellular areas (2.7+/-0.5 versus 1.2+/-0.5, p=0.032). Positive immunostaining of the superficial epithelium was frequently detected in refractory patients (apical: 9/11 cases, cytoplasmic: 10/11 cases) but was only observed in 4/8 responders. P-gp was also detected in similar areas of the crypt epithelium in 6/11 refractory patients, while it was infrequent in the group of 8 responders (1 apical 1 case, cytoplasmic 2 cases). Samples from the mucosa of normal ileal pouch-anal anastomoses obtained several years after the surgical procedure had a P-gp immunostaining pattern which was similar to that of rectal samples from patients with refractory UC. CONCLUSIONS: These results suggest a critical role of P-gp overexpression in steroid-refractory UC.
Antecedentes. La glicoproteína P (P-gp), un producto del gen MDR-1, es una bomba de eflujo transmembranainvolucrada en el transporte de drogas, descripta por primera vez en el cáncer refractario. En el intestino normal, P-gp se detecta sobre las célulasepiteliales superficiales, pero no se la ha descripto en el epitelio de las criptas. El papel de P-gp y su expresiónintestinal en la colitis ulcerosa (CU) refractaria a esteroides es controvertido. Objetivo. Comparar elpatrón de inmunotinción de P-gp en células epiteliales colónicas de pacientes con CU refractaria vs.respondedora a esteroides. Métodos. Se estudió P-gp por inmunohistoquímica en biopsias rectales obtenidasde 19 pacientes con CU activa, incluyendo muestras prequirúrgicas de 11 pacientes refractarios que fueronsometidos a una colectomía y muestras de 8 respondedores. Ideamos un score de 5 puntos (0-4), según elporcentaje de superficie epitelial con inmunotinción positiva en el epitelio superficial y críptico (áreas apical,lateral y citoplásmica). Resultados. Comparados con los respondedores, los pacientes refractarios a esteroides tenían scores de inmunotinción significativamente mayores en el epitelio superficial, tanto en lasáreas celulares apical (2.8+0.5 vs. 1.1+0.5, p=0.023) como citoplásmica (2.7+0.5 vs. 1.2+0.5, p=0.032). Se detectó frecuentemente inmunotinción positiva en el epitelio superficial en los pacientes refractarios (apical: 9/11 casos, citoplásmica: 10/11 casos), pero la misma se observó sólo en 4/8 respondedores. P-gp también sedetectó en áreas similares del epitelio de las criptas en 6/11 pacientes refractarios, en tanto que fue infrecuenteen el grupo de los 8 respondedores (1 caso en el área apical y 2 en la citoplásmica). Fuerón estudiadasbiopsias de la mucosa de la anastomosis pouch ileal - anal, obtenidas varios años después del procedimeinto quirúrgico, observándose un patrón de...
Subject(s)
Humans , Colitis, Ulcerative/genetics , Genes, MDR , ATP Binding Cassette Transporter, Subfamily B, Member 1/analysis , Immunohistochemistry , Biopsy , Colonic Pouches , Colitis, Ulcerative/metabolism , Colon/chemistry , Epithelial Cells/chemistry , Gene Expression , Intestinal Mucosa/chemistryABSTRACT
El transportador multidrogas P-glicoproteína (Pgp) lleva a cabo el eflujo celular, ATP-dependiente, de muchas drogas hidrofóbicas, productos naturales y péptidos. Se propone que la Pgp contiene dos sitios de transporte, conocidos como los sitios -H y -R por sus preferencias por Hoechst 33342 (H33342) y rodamina 123, respectivamente. Cuando H33342 interactúa con la Pgp purificada, su rendimiento cuántico incrementa debido al ambiente hidrofóbico del bolsillo de enlazamiento H. En este trabajo, estudiamos el enlazamiento de H33342 a la Pgp empleando experimentos cinéticos en la modalidad de stoppedflow. El curso temporal de la reacción fue seguido por el incremento de la fluorescencia del colorante y analizado con la herramienta computacional DYNAFIT, usando un modelo donde una reacción bimolecular rápida, es seguida por tres isomerizaciones secuenciales. Adicionalmente, bajo condiciones de seudo-primer-orden (exceso del ligando), la reacción presentó cuatro relajaciones caracterizadas por cuatro constantes de tiempo (á`s) y cuatro amplitudes (A¡`s) Estos parámetros fueron analizados utilizando la técnica de la matriz de los operadores de proyección. Esta aproximación aportó, por primera vez, información acerca de las constantes de velocidad y propiedades fluorescentes de los diversos intermediarios formados durante el enlazamiento de H33342 a la Pgp.
The P-glycoprotein multidrug transporter (Pgp) carries out ATP-driven cellular efflux of many different hydrophobic drugs, natural products, and peptides. Pgp is proposed to contain two drug transport sites, known as the H site and the R site for their preference for Hoechst 33342 (H33342) and rhodamine 123, respectively. When H33342 interacts with purified Pgp, its quantum yield is increased due to transfer to a hydrophobic environment within the H binding pocket, as shown by the steady-state fluorescence emission. In this work, we studied the binding of H33342 to Pgp using stopped-flow kinetic experiments. The time course of the reaction was followed by enhancement of dye fluorescence and analyzed by the computational tool DYNAFIT, using the model of a fast bimolecular reaction, followed by a three-step sequential isomerization. Additionally, under pseudo-first-order conditions (excess ligand), the reaction presented five normal modes, characterized by four relaxation times (á`s) and four amplitudes (A¡`s) These parameters were analyzed using the matrix projection operator technique, considering a four-step sequential reaction. This approach provides, for the first time, information about the rate constants and fluorescent properties of the diverse intermediates formed during the binding of H33342 to Pgp.
Subject(s)
Fluorescence , Kinetics , ATP Binding Cassette Transporter, Subfamily B, Member 1/analysis , ATP Binding Cassette Transporter, Subfamily B, Member 1/chemistry , BiologyABSTRACT
El objetivo de este trabajo fue estudiar la distribución de la expresión de la Gp-P y su ARNm en sangre periférica de una amplia población de sujetos sanos para identificar probables diferencias individuales. Para ello se estudiaron un total de 126 muestras sanguíneas mediantes inmunofluorescencia directa, por citometría de flujo, con el anticuerpo monoclonal JSB1 conjugado con FITC. Los parámetros a evaluar fueron el número de células positivas (por ciento POS) e incorporación media de fluorescencia específica (IMFE). Posteriormente, se estudió el ARNm del gen MDR1 por RT-PCR. Los resultados mostraron que en aproximadamente el 82 por ciento de los individuos estudiados, la IMFE presentó valores entre 10 y 25 en las tres subpoblaciones celulares de sangre periférica; en los linfocitos y monocitos, se observó además que un grupo de donantes, no superior al 10 por ciento, presentaron valores de IMFE menores de 10 y mayores de 25. Entre los subpoblaciones celulares, el por ciento POS más elevado correspondió a los linfocitos (t de student; p<0.001). Los resultados del estudio de ARNm del gen MDR1 por TR-PCR mostró correlación con los valores obtenidos por citometría del flujo. Se concluye que el estudio de la Glicoproteína P en el leucocitos de sangre periférica en una población de individuos sanos, pone de manifiesto la existencia de variabilidad individual en los niveles de expresión, lo que hace suponer un condicionamiento genético de control de los niveles de expresión basal de la Gp-P
Subject(s)
Humans , Male , Female , Leukocytes , Lymphokines , Monocytes , ATP Binding Cassette Transporter, Subfamily B, Member 1/analysis , ATP Binding Cassette Transporter, Subfamily B, Member 1/pharmacologyABSTRACT
The phenomenon of multidrug resistance (MDR), representing cross-resistance among a number of unrelated chemotherapeutic drugs, is the major cause of chemotherapy failure in many tumors. It has been also detected in leukemias and in these cancers, as well as in many others, resistance can be reversed by a number of substances known as modulators or reversing agents. The capacity of identifying tumors resistant to chemotherapy could orientate the treatment employed. In leukemias, tumor cells are easily obtainable and many techniques have been used to evaluate resistance in these cells. Studying 42 leukemia patients we found a correlation of nearly 60 per cent among surface expression of P-glycoprotein, in vitro resistance reversal by cyclosporin A (CS-A) and extrusion of the rhodamine 123 dye. This latter assay has the advantage of measuring a functional aspect related to resistance (intracellular drug accumulation), being reproducible and affordable by most laboratories. The data generated by this assay were in accordance with those reported by other authors using different methods. To allow for an experimental approach in the study of MDR in leukemias, an in vitro model of a vincristine-induced erythroleukemia resistant cell line was established by us, and was shown to display MDR characteristics: resistance to unrelated drugs, surface expression of P-glycoprotein, extrusion of rhodamine 123 and resistance reversal by trifluoperazine, a reversing agent. Furthermore, this vincristine-resistant line was as sensitive to cell mediated lysis by natural killer (NK) cells as the parental line. Models like this one allow for the in vitro testing of new reversing agents, and when combined to in vitro tests for NK and LAK activity, may select for substances capable of modulating resistance without affecting a potentially useful cell mediated immunotherapy.